Search

Bleeding and Thrombosis

The objectives of the SWG on ‘Bleeding and Thrombosis’ are:

To promote education in the field of blood coagulation, including mechanisms, prevention, and treatment of bleeding and thrombotic disorders.

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dec 23 2020

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

Dec 08 2023

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

Jun 13 2014 Posted in Press releases

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

José Carreras Award handed out at the 17th Congress of EHA

Jun 15 2012 Posted in Press releases

He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.

Thrombocytopenias and Platelet Function Disorders

The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.